215 related articles for article (PubMed ID: 4421448)
21. [Extrapancreatic effects of sulfonylurea compounds. II. Comparison of equimolar concentrations of tolbutamide, glibornuride, hydroxymethyltolbutamide, carboxytolbutamide, and carboxyglycylamide with reference to their blood-sugar-decreasing and antilipolytic effect on completely pancreatectomized dogs, chronically treated insulin].
Beyer J; Cordes U; Sell G; Krall H; Schöffling K
Arzneimittelforschung; 1972 Dec; 22():Suppl 12A:2172. PubMed ID: 4679247
[No Abstract] [Full Text] [Related]
22. Hypoglycemic and hypotriglyceridemic effects of tolbutamide in triphenyltin chloride-induced diabetic rabbits.
Watanabe M; Watanabe K; Matsui H
Vet Hum Toxicol; 2002 Jun; 44(3):140-4. PubMed ID: 12046964
[TBL] [Abstract][Full Text] [Related]
23. Investigation of the effects of sulfonylurea exposure on pancreatic beta cell metabolism.
Brennan L; Hewage C; Malthouse JP; McClenaghan NH; Flatt PR; Newsholme P
FEBS J; 2006 Nov; 273(22):5160-8. PubMed ID: 17054712
[TBL] [Abstract][Full Text] [Related]
24. Studies on oral hypoglycemia agents -- blood levels and hypoglycemic effects of sulfonylurea compounds--.
Fukuchi H; Tsukiai S; Kumagai M; Kitaura T
Hiroshima J Med Sci; 1977 Dec; 26(4):269-76. PubMed ID: 615173
[No Abstract] [Full Text] [Related]
25. Correlation among glucose, insulin, and orally administered SPC-703 blood-levels in rats and rabbits.
Wójcikowski C; Strzelecki T; Szlabowicz D
Pol J Pharmacol Pharm; 1975; 27(1):45-52. PubMed ID: 1114135
[No Abstract] [Full Text] [Related]
26. A study of the possible interaction of indoprofen with hypoglycemic sulfonylureas in diabetic patients.
Pedrazzi F; Bommartini F; Freddo J; Emanueli A
Eur J Rheumatol Inflamm; 1981; 4(1):26-31. PubMed ID: 7042358
[TBL] [Abstract][Full Text] [Related]
27. [The blood-sugar depressing and betacytotrope effect of glibornurid in healthy and in gastric-resected persons (author's transl)].
Grabner W; Matzkies F; Randerbrock V; Berg G
Med Klin; 1973 Aug; 68(34):1101-5. PubMed ID: 4598149
[No Abstract] [Full Text] [Related]
28. Effects of chronic and acute treatment with sulfonylureas on plasma insulin and glucose levels in the rat.
Codina J; Lasuncion MA; Herrera E
Diabete Metab; 1978 Mar; 4(1):47-52. PubMed ID: 97105
[No Abstract] [Full Text] [Related]
29. [Derivatives of 2-mercaptobenzenesulphonylamide. IV. Synthesis and properties of some hypoglycemic agents derived from N-(4-chloro-2-mercapto-5-methylbenzenesulphonyl)urea].
Brzozowski Z; Wójcikowski C
Acta Pol Pharm; 1990; 47(3-4):45-8. PubMed ID: 12959242
[TBL] [Abstract][Full Text] [Related]
30. [Pharmacology of HB 419, a new strongly effective oral antidiabetic].
Bänder A; Pfaff W; Schmidt FH; Stork H; Schröder HG
Arzneimittelforschung; 1969 Aug; 19(8):Suppl:1363-8. PubMed ID: 5394454
[No Abstract] [Full Text] [Related]
31. [The effect of oral antidiabetics on the biosynthesis of proinsulin in the rat].
Tjioe TO; Wacker A
Arzneimittelforschung; 1972 Nov; 22(11):1890-2. PubMed ID: 4633587
[No Abstract] [Full Text] [Related]
32. [Effects of some sulfonylurea derivatives on liver extracts cultivated in vitro. I. Morphology].
Conti G; Hadhazy C; Cappelli B; Spreca A; Gotzos V
Pharm Acta Helv; 1971 Aug; 46(8):497-507. PubMed ID: 5092968
[No Abstract] [Full Text] [Related]
33. The pharmacology S 1702, a new highly effective oral antidiabetic drug with unusual properties. 3. Antistickiness activity, fibrinolytic properties and haemostatic parameters study.
Desnoyers P; Labaume J; Anstett M; Herrera M; Pesquet J; Sebastien J
Arzneimittelforschung; 1972 Oct; 22(10):1691-5. PubMed ID: 4677058
[No Abstract] [Full Text] [Related]
34. [Mechanism of action of AR 3-ARDF 26, a new betacytotropic sulfonylurea derivative and tolbutamide].
Zilker T; Bottermann P
Verh Dtsch Ges Inn Med; 1972; 78():1275-8. PubMed ID: 4665516
[No Abstract] [Full Text] [Related]
35. Oral hypoglycemic agents.
N Engl J Med; 1977 Aug; 297(7):394-6. PubMed ID: 406566
[No Abstract] [Full Text] [Related]
36. The pharmacology of a new hypoglycaemic agent N-[4-(2-(2,3-dihydrobenzo(b)furan-m-carboxamido)-ethyl)-benzenesulphonyl]-N'-cyclohexylurea (NOVO CS 476). I. Pharmacological studies on the hypoglycaemic effect.
Jorgensen KD
Acta Pharmacol Toxicol (Copenh); 1977 Feb; 40(2):216-26. PubMed ID: 402791
[TBL] [Abstract][Full Text] [Related]
37. Involvement of nitric oxide (NO) in hypoglycaemic activity of tolbutamide.
Satyanarayana S; Krishnaiah YS; Rao BK
Indian J Physiol Pharmacol; 1998 Oct; 42(4):551-4. PubMed ID: 10874360
[TBL] [Abstract][Full Text] [Related]
38. Oral hypoglycemic agents: the pharmacological basis of their clinical use.
Davidoff F
R I Med J; 1973 Oct; 56(10):409-14. PubMed ID: 4518221
[No Abstract] [Full Text] [Related]
39. [Experimental and clinical pharmacology of oral antidiabetics].
Cuomo V; Marino A
Clin Ter; 1972 Sep; 62(6):505-52. PubMed ID: 4674507
[No Abstract] [Full Text] [Related]
40. Comparative hypoglycemic and hypoketonemic effects of tolbutamide and glypentide in rat.
García-Rafanell J; Lasunción MA; Morell J; Herrera E
Rev Esp Fisiol; 1977 Jun; 33(2):103-7. PubMed ID: 877376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
